Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Boehringer Ingelheim To Build Tech Center
by Ann M. Thayer
June 11, 2012
| A version of this story appeared in
Volume 90, Issue 24
Boehringer Ingelheim will spend more than $62 million to build a facility for producing new active pharmaceutical ingredients at the company’s Biberach, Germany, site. The new facility will make clinical-scale quantities of compounds arising from the firm’s own drug development pipeline. The pilot plant facility will have 15 reactors with volumes from 100 to 300 L and four manufacturing bays, including four synthesis labs for scale-up work. Boehringer expects to complete construction of the plant and associated tech center in early 2014.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter